Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab in Active Thyroid Eye Disease
NCT01868997Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2013
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in thyroid eye disease (TED) comparing Placebo with Teprotumumab (2 arms). Primary endpoint: Responder Status at 24 weeks. Started Jul 2013; status: completed.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT01868997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01868997.